Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MLN2480 + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**MLN2480 + paclitaxel** is an investigational combination therapy consisting of MLN2480 (also known as TAK-580), a small molecule pan-RAF inhibitor (targeting ARAF, BRAF, and CRAF kinases), with paclitaxel, a microtubule stabilizer widely used as a chemotherapeutic. MLN2480 inhibits RAF kinases, thereby blocking the MAPK/ERK signaling pathway that is frequently upregulated in cancer. Paclitaxel disrupts cell division by stabilizing microtubules and promoting apoptosis. This combination is being evaluated in adult patients with advanced nonhematologic malignancies, particularly those who have failed standard therapies.
- Other names
- MLN2480MLN-2480MLN 2480TAK-580TAK580TAK 580paclitaxel
02
Targets
ARAF (Proto-oncogene serine/threonine-protein kinase A-Raf)BRAF (B-Raf proto-oncogene, serine/threonine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on MLN2480 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MLN2480 + paclitaxel.